These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 18237796)
1. PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Supiot S; Zhao H; Wiman K; Hill RP; Bristow RG Radiother Oncol; 2008 Mar; 86(3):407-11. PubMed ID: 18237796 [TBL] [Abstract][Full Text] [Related]
2. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Liang Y; Besch-Williford C; Hyder SM Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255 [TBL] [Abstract][Full Text] [Related]
3. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells. Liang Y; Besch-Williford C; Benakanakere I; Hyder SM Int J Oncol; 2007 Oct; 31(4):777-84. PubMed ID: 17786308 [TBL] [Abstract][Full Text] [Related]
4. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors. Liang Y; Besch-Williford C; Benakanakere I; Thorpe PE; Hyder SM Breast Cancer Res Treat; 2011 Jan; 125(2):407-20. PubMed ID: 20349129 [TBL] [Abstract][Full Text] [Related]
5. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells. Cuddihy AR; Jalali F; Coackley C; Bristow RG Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811 [TBL] [Abstract][Full Text] [Related]
6. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Supiot S; Hill RP; Bristow RG Mol Cancer Ther; 2008 Apr; 7(4):993-9. PubMed ID: 18413812 [TBL] [Abstract][Full Text] [Related]
7. PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells. Russo D; Ottaggio L; Penna I; Foggetti G; Fronza G; Inga A; Menichini P Biochem Biophys Res Commun; 2010 Nov; 402(2):345-50. PubMed ID: 20946886 [TBL] [Abstract][Full Text] [Related]
8. PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins. Rökaeus N; Klein G; Wiman KG; Szekely L; Mattsson K Oncogene; 2007 Feb; 26(7):982-92. PubMed ID: 16909106 [TBL] [Abstract][Full Text] [Related]
9. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer? Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392 [TBL] [Abstract][Full Text] [Related]
10. Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine. Orue A; Chavez V; Strasberg-Rieber M; Rieber M BMC Cancer; 2016 Nov; 16(1):902. PubMed ID: 27863474 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249. Shi H; Lambert JM; Hautefeuille A; Bykov VJ; Wiman KG; Hainaut P; Caron de Fromentel C Carcinogenesis; 2008 Jul; 29(7):1428-34. PubMed ID: 18048389 [TBL] [Abstract][Full Text] [Related]
12. Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells. Nguyen KH; Hachem P; Khor LY; Salem N; Hunt KK; Calkins PR; Pollack A Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):238-46. PubMed ID: 15993550 [TBL] [Abstract][Full Text] [Related]
13. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627 [TBL] [Abstract][Full Text] [Related]
15. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study. Benakanakere I; Besch-Williford C; Ellersieck MR; Hyder SM Endocr Relat Cancer; 2009 Mar; 16(1):85-98. PubMed ID: 19075036 [TBL] [Abstract][Full Text] [Related]
16. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax. Wang T; Lee K; Rehman A; Daoud SS Biochem Biophys Res Commun; 2007 Jan; 352(1):203-12. PubMed ID: 17113036 [TBL] [Abstract][Full Text] [Related]
17. Antitumor Effects of PRIMA-1 and PRIMA-1 Menichini P; Monti P; Speciale A; Cutrona G; Matis S; Fais F; Taiana E; Neri A; Bomben R; Gentile M; Gattei V; Ferrarini M; Morabito F; Fronza G Cells; 2021 Jan; 10(1):. PubMed ID: 33430525 [TBL] [Abstract][Full Text] [Related]
19. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Lambert JM; Gorzov P; Veprintsev DB; Söderqvist M; Segerbäck D; Bergman J; Fersht AR; Hainaut P; Wiman KG; Bykov VJ Cancer Cell; 2009 May; 15(5):376-88. PubMed ID: 19411067 [TBL] [Abstract][Full Text] [Related]
20. Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells. Lee K; Wang T; Paszczynski AJ; Daoud SS Biochem Biophys Res Commun; 2006 Oct; 349(3):1117-24. PubMed ID: 16970918 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]